SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-025932
Filing Date
2022-05-12
Accepted
2022-05-12 16:05:25
Documents
13
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159842-8k_immucell.htm   iXBRL 8-K 26459
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 12, 2022 ea159842ex99-1_immucell.htm EX-99.1 54977
  Complete submission text file 0001213900-22-025932.txt   263137

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20220512.xsd EX-101.SCH 3033
4 XBRL LABEL FILE iccc-20220512_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE iccc-20220512_pre.xml EX-101.PRE 22595
7 EXTRACTED XBRL INSTANCE DOCUMENT ea159842-8k_immucell_htm.xml XML 3484
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 22917727
SIC: 2835 In Vitro & In Vivo Diagnostic Substances